In Q4 2024, Tang Capital Management held 133 positions worth $1.3B. They initiated 20 new positions and exited 57. Their largest holding was TARS ($124.8M). Portfolio value grew +9.1% versus the prior quarter.
Frequently asked questions
What stocks did Tang Capital Management own in Q4 2024?
Tang Capital Management held 133 biotech stocks in their 13F portfolio in Q4 2024. Their top positions include TARS, AUPH, GLPGF, EOLS, MIRM. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Tang Capital Management's portfolio worth in Q4 2024?
Tang Capital Management's tracked biotech portfolio was worth $1.3B across 133 positions, with total assets under management of approximately $2B. Portfolio values are based on 13F filings with the SEC.
What did Tang Capital Management buy in Q4 2024?
Tang Capital Management initiated 20 new positions in Q4 2024, including LEGN, EWTX, BIOA, GRAL, STOK and 15 more. They also increased 50 existing positions.
What did Tang Capital Management sell in Q4 2024?
Tang Capital Management fully exited 57 positions in Q4 2024, including STIM, NKTR, LIANY, GOSS, WGSWW and 52 more. They also trimmed 13 existing positions.
Is Tang Capital Management a biotech fund?
Event-driven biotech specialist known for concentrated bets around clinical catalysts, M&A situations, and activist campaigns. Deep industry relationships and willingness to engage publicly make the fund a closely watched market signal.
Want AI analysis, insider signals, and catalyst overlays for Tang Capital Management?
View latest Tang Capital Management portfolio →